P/E ratio for Esperion Therapeutics (ESPR)

P/E ratio history for Esperion Therapeutics from 2013 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Ultragenyx RARE	-4.54	418.46%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	81.2	-9,366.53%	🇺🇸 USA
Pfizer PFE	13.5	-1,636.07%	🇺🇸 USA
Regeneron Pharmaceuticals REGN	20.1	-2,391.82%	🇺🇸 USA
Amicus Therapeutics FOLD	-14.9	1,600.26%	🇺🇸 USA
Lexicon Pharmaceuticals LXRX	-1.18	34.60%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.